Bevasiranib sodium
Modify Date: 2024-09-13 23:52:17
Bevasiranib sodium structure
|
Common Name | Bevasiranib sodium | ||
|---|---|---|---|---|
| CAS Number | 849758-52-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Bevasiranib sodiumBevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD). |
| Name | Bevasiranib sodium |
|---|
| Description | Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD). |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |